NW Bio's DCVax Featured On Fox News And Fox Business News

NYU's Dr. Marc Siegel Discusses DCVax And Its Life-Extending Potential As A Cancer Therapy

News provided by

Nov 08, 2013, 08:15 ET

BETHESDA, Md., Nov. 8, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO)(NW Bio), a biotechnology company developing non-toxic DCVax^® personalized immune therapies for solid tumor cancers, announced today that their vaccine was featured yesterday in news coverage on both Fox News and Fox Business News.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

The segment was hosted for Fox by Dr. Marc Siegel, a Clinical Associate Professor at NYU's Langone Medical Center, who describes Northwest Biotherapeutics's DCVax as a potential life-extending treatment for all solid tumor cancers by using biomarkers from the patient's own tumor cells to activate the patient's immune system to fight the cancer in the patient's body.

Dr. Lee Tessler, participating in a current late stage Phase III trial of the DCVax immune therapy for brain cancer at the Long Island Brain Tumor Center, describes the process that begins with surgical removal of the patient's tumor. The patient's immune cells are then harvested and exposed in the laboratory to the biomarkers taken from the patient's tumor. These conditioned immune cells are then injected back into the patient through a simple injection under the skin in the upper arm, similar to a flu shot. The conditioned ("educated") immune cells then mobilize the patient's immune system to now fight any tumor cells bearing the same biomarkers wherever such tumor cells are found in the body.

According to Dr. Siegel, some patients with Glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer, in preliminary trials have seen their survival times more than double from what would be expected under the current standard of care (which consists of surgical removal of the tumor, radiation and chemotherapy). The final (Phase III) stage of DCVax clinical trials for GBM is being conducted at more than 50 sites across the US, as well as in Europe.

"Each cancer vaccine is personalized, and it takes just eight days to produce enough for three-to-five years' worth of treatment," remarks Dr. Siegel. "It's more cost-effective than older cancer vaccines, and the side effects are minimal versus standard treatments."

"We appreciate Fox News bringing our DCVax immune therapy to the attention of patients and others, as there is a desperate need for new and better treatments for brain cancer," commented Linda F. Powers, CEO NW Bio. "The prognosis for patients receiving standard of care treatment has not materially changed in decades. But DCVax now has the potential to significantly improve and extend the lives of cancer patients suffering from all types of solid tumor cancers, both operable and inoperable, without the toxic side effects associated with existing treatments."

To view the Fox segments, please visit the following link: http://video.foxnews.com/v/2814859046001/could-our-own-bodies-hold-the-key-to-the-curing-cancer/?playlist_id=930909757001

About Northwest Biotherapeutics

Northwest Biotherapeutics is developing cancer vaccines to treat a broad range of solid tumor cancers that are more effective than current treatments without the side effects of chemotherapeutic drugs. NW Bio's proprietary manufacturing technology enables the Company to produce its individualized vaccine both in the U.S. and Europe in an efficient, cost-effective manner. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company's lead program, DCVax-L, is in a 312-patient Phase III trial in patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. The Company has also received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and is currently conducting a 60-patient Phase I/II trial for direct injection of a more potent dendritic cell into all inoperable solid tumor cancers. The Company has also conducted a Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy. Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

SOURCE Northwest Biotherapeutics